2023年度決算説明会 成長と株主還元へのコミットメント

最初から再生

成長と株主還元へのコミットメント

重要な注意事項

• Introduction & ビジネスハイライト

Better Health for People,Brighter Future for the World

FY2023 Results: Delivered or Exceeded Management Guidance

Positioned for Return to Revenue & Profit Growth from FY2025 with Efficiency Program to Deliver Margin Expansion

Enterprise-wide Program to Drive Efficiencies and Deliver 100-250bps of Core Operating Profit Margin Improvement Each Year From FY2025

Incorporating Data, Digital & Technology Across the Value Chain to Develop and Deliver Medicines to Patients more Efficiently

Growth & Launch Products Expected to Represent ~50% of Total Revenue in FY2024 with Double-digit Growth Outlook at CER

Wntyvio Expect Return to Double-digit Revenue Growth in FY2024

Plasma-Derived Therapies a Steady Long-term Growth Driver

• パイプラインアップデート

Key FY23 Pipeline Achievements Yields Maturing Late-Stage Pipeline

Developing Life Transforming Medicines for Rare and More Prevalent Diseases: Six Late-Stage Programs have the Potential to Generate Significant Value

Data Driven Decisions in FY23 Ensure Focus on the Most Promising Programs Across Three Core Therapeutic Areas

@

Impactful Pipeline Milestones for Early to Mid-Stage Programs Address Unmet Patient Needs and Advance Science

Upcoming Pipeline Milestones and Key Data Presentations

Mezagitamab (TAK-079): Anti-CD38 Antibody with Autoimmune Disease Modifying Potential Entering Phase 3

• 財務報告
  

FY2023 Revenue +1.5% at CER Despite Significant LOE Impact;Reported Profits Impacted by Impairments of ALOFISEL & EXKIVITY

FY2023 Revenue Growth +1.5% at CER Despite Significant LOE Impact

FY2023 Core Operating Profit Impacted by LOE of Higher Margin Products & Investment in R&D and Data, Digital & Technology

FY2023 Reported Operating Profit Decline Reflects Impairments of ALOFISEL & EXKIVITY as well as Higher Other Operating Expenses

FY2023 Free Cash Flow Exceptionally Low Because of VYVANSE LOE Impact, Litigation-related Payment, and CAPEX for Business Development

FY2024 Outlook for Continued Decline of VYVANSE in the U.S.; Investing for Growth While Driving Efficiency to Deliver JPY 1 Trn Core Op Profit

FY2024 Revenue Flat to Slightly Declining at CER, with Growth & Launch ProductsMomentum More than Offset by Continued Impact of LOE Including VYVANSE

Core Operating Profit Growth Declining due to VYVANSE Erosion & Modest Increase in R&D and DD&T Investment to Drive Long-term Competitiveness

Enterprise-wide Program to Drive Efficiencies and Deliver 100-250bps of Core Operating Profit Margin Improvement Each Year From FY2025

Committed to Growth & Shareholder Returns

Positioned for Return to Revenue & Profit Growth from FY2025 with Efficiency Program to Deliver Margin Expansion

質疑応答

• 質疑応答1

• 質疑応答2

• 質疑応答3

• 質疑応答4

• 質疑応答5

• 質疑応答6

• 質疑応答7

• 質疑応答8

• 質疑応答9

APPENDIX

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@